Program
vepdegestrant
Also written as “ARV-471”, “Vepdegestrant” and “[phenyl-14C]ARV-471”.
Its studies are mostly in Breast Neoplasms, led by 3 companies.
Drug pageVepdegestrant: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 176 open or running | phase 3since Nov 16, 2022 | Jul 14, 2022 | Dec 4, 2026phase 1 · NCT07231991 |
| Arvinas Estrogen Receptorits history only | 20 open or running | phase 2since Aug 27, 2019 | Aug 27, 2019 | none ahead |
| Arvinasits history only | 10 open or running | phase 2since Sep 7, 2022 | Sep 7, 2022 | none ahead |
Also a collaborator on its studies: Carrick Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 6 earlier studies, Aug 27, 2019 to Sep 8, 2022.
- Jul 21, 2022Named vepdegestrantINNProposed as its International Nonproprietary Name in WHO's List 127 · before, ARV-471
- Oct 5, 2022Phase 2 study in Breast NeoplasmsPfizer · NCT05573555 · 20 enrolled · United States, Canada, Italy and more
- Nov 16, 2022Phase 3 study in Breast NeoplasmsPfizer · NCT05654623 · 624 enrolled · United States, Argentina, Australia and more
- Dec 7, 20222 phase 1 studies in HealthyPfizer · NCT05652660, NCT05673889
- Jan 17, 2023Phase 1 study in Breast NeoplasmsPfizer · NCT05732428 · 9 enrolled · China
- May 25, 2023Phase 3 study in Breast NeoplasmsPfizer · NCT05909397 · 59 enrolled · United States, Australia, Brazil and more
- Jun 8, 2023Phase 1 study in HealthyPfizer · NCT05930925 · 12 enrolled · United States
- Aug 15, 2023Phase 1 study in Healthy ParticipantsPfizer · NCT06005688 · 12 enrolled · Belgium
- Oct 16, 2023Phase 2 study in Breast NeoplasmsPfizer · NCT06125522 · 11 enrolled · United States, Belgium, France and more
- Dec 13, 2023Phase 2 study in Breast NeoplasmsPfizer · NCT06206837 · 71 enrolled · United States, Belgium, Canada and more
- Feb 5, 20242 phase 1 studiesPfizer · NCT06256510, NCT06275841
- Mar 28, 2025Phase 1 study in Healthy ParticipantsPfizer · NCT06911788 · 10 enrolled · Netherlands
- Nov 13, 2025Phase 1 study in Healthy ParticipantsPfizer · NCT07231991 · 24 planned · United States
- Oct 27, 2026Phase 2 study terminatedStudy stoppedNCT05573555 · “Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. The decision was not related to…”
- Oct 27, 2026Phase 2 study terminatedStudy stoppedNCT06125522 · “Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. The decision was not related to …”
Ahead
- Dec 4, 2026Primary completion: phase 1 study in Healthy ParticipantsPfizer · NCT07231991
- Dec 30, 2026Primary completion: phase 3 study in Breast NeoplasmsPfizer · NCT05909397
- Mar 24, 2027Primary completion: phase 2 study in Breast NeoplasmsPfizer · NCT05548127
TargetBeta
“An orally available hetero-bifunctional molecule and selective estrogen receptor (ER) alpha-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, ”NCIt, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07231991Healthy Participants · United States | 1 | Recruiting | Pfizer | Dec 4, 2026 | 24 |
| NCT06911788Healthy Participants · Netherlands | 1 | Completed | Pfizer | May 23, 2025 | 10 |
| NCT06275841Healthy · United States | 1 | Completed | Pfizer | May 3, 2024 | 12 |
| NCT06256510Healthy Participants · Belgium | 1 | Completed | Pfizer | Apr 16, 2024 | 15 |
| NCT06206837Breast Neoplasms · United States, Belgium, Canada and more | 2 | Active, not recruiting | Pfizer | Sep 5, 2025 | 71 |
| NCT06125522Breast Neoplasms · United States, Belgium, France and more | 2 | Terminated | Pfizer | Sep 10, 2026 | 11 |
| NCT06005688Healthy Participants · Belgium | 1 | Completed | Pfizer | Oct 11, 2023 | 12 |
| NCT05930925Healthy · United States | 1 | Completed | Pfizer | Jul 27, 2023 | 12 |
| NCT05909397Breast Neoplasms · United States, Australia, Brazil and more | 3 | Active, not recruiting | Pfizer | Dec 30, 2026 | 59 |
| NCT05732428Breast Neoplasms · China | 1 | Completed | Pfizer | Mar 29, 2024 | 9 |
| NCT05673889Healthy · Belgium | 1 | Completed | Pfizer | Mar 15, 2023 | 24 |
| NCT05652660Healthy · United States | 1 | Completed | Pfizer | Feb 9, 2023 | 12 |
| NCT05654623Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Pfizer | Jan 31, 2025 | 624 |
| NCT05573555Breast Neoplasms · United States, Canada, Italy and more | 2 | Terminated | Pfizer | Oct 6, 2026 | 20 |
| NCT05538312Healthy · Belgium | 1 | Completed | Pfizer | Apr 24, 2023 | 12 |
| NCT05549505Breast Neoplasms · United States, Georgia, Germany and more | 2 | Completed | Arvinas | Jul 13, 2024 | 152 |
| NCT05548127Breast Neoplasms · United States, Canada, Italy and more | 2 | Active, not recruiting | Pfizer | Mar 24, 2027 | 37 |
| NCT05501769Breast Neoplasms · United States, Spain | 1 | Completed | Arvinas Estrogen Receptor | Jul 3, 2024 | 32 |
| NCT05463952Breast Neoplasms · Japan | 1 | Active, not recruiting | Pfizer | May 4, 2023 | 6 |
| NCT04072952Breast Neoplasms · United States | 2 | Completed | Arvinas Estrogen Receptor | Sep 13, 2024 | 219 |
How it is read
Names in the registry
- “ARV-471”, 7 entries
- “vepdegestrant”, 6 entries
- “Vepdegestrant”, 4 entries
- “[phenyl-14C]ARV-471”, 1 entry
- “[oxoisoindolin-14C]ARV-471”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 11 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.